The neuroprotective role of metformin in advanced glycation end product treated human neural stem cells is AMPK-dependent.

[1]  D. Hardie,et al.  AMPK: positive and negative regulation, and its role in whole-body energy homeostasis. , 2015, Current opinion in cell biology.

[2]  D. Butterfield,et al.  Elevated risk of type 2 diabetes for development of Alzheimer disease: a key role for oxidative stress in brain. , 2014, Biochimica et biophysica acta.

[3]  J. Boyle,et al.  P179Celecoxib-mediated activation of an AMPK-CREB-Nrf2 dependent pathway: a novel mechanism for endothelial cytoprotection in chronic systemic inflammation , 2014 .

[4]  Vincenzo Bonifati,et al.  Effect of resveratrol on mitochondrial function: implications in parkin-associated familiar Parkinson's disease. , 2014, Biochimica et biophysica acta.

[5]  I. Lucki,et al.  High fat diet produces brain insulin resistance, synaptodendritic abnormalities and altered behavior in mice , 2014, Neurobiology of Disease.

[6]  S. López-Briones,et al.  A PPARγ, NF-κB and AMPK-Dependent Mechanism May Be Involved in the Beneficial Effects of Curcumin in the Diabetic db/db Mice Liver , 2014, Molecules.

[7]  Yan Zhou,et al.  Metformin inhibits StAR expression in human endometriotic stromal cells via AMPK-mediated disruption of CREB-CRTC2 complex formation. , 2014, The Journal of clinical endocrinology and metabolism.

[8]  V. Holla,et al.  Synergistic Therapeutic Vascular Cytoprotection against Complement-Mediated Injury Induced via a PKCα-, AMPK-, and CREB-Dependent Pathway , 2014, The Journal of Immunology.

[9]  L. Lim,et al.  Aminoguanidine inhibits the AGE-RAGE axis to modulate the induction of periodontitis but has limited effects on the progression and recovery of experimental periodontitis: a preliminary study. , 2014, Journal of periodontology.

[10]  K. Chandrasekaran,et al.  PGC-1α regulation of mitochondrial degeneration in experimental diabetic neuropathy , 2014, Neurobiology of Disease.

[11]  N. Inestrosa,et al.  Signaling pathway cross talk in Alzheimer’s disease , 2014, Cell Communication and Signaling.

[12]  H. Y. Lee,et al.  Neuroprotective effect of osmotin against ethanol-induced apoptotic neurodegeneration in the developing rat brain , 2014, Cell Death and Disease.

[13]  M. Xilouri,et al.  The protective role of AMP-activated protein kinase in alpha-synuclein neurotoxicity in vitro , 2014, Neurobiology of Disease.

[14]  J. Prehn,et al.  Bmf upregulation through the AMP-activated protein kinase pathway may protect the brain from seizure-induced cell death , 2013, Cell Death and Disease.

[15]  S. Correia,et al.  Crosstalk between diabetes and brain: glucagon-like peptide-1 mimetics as a promising therapy against neurodegeneration. , 2013, Biochimica et biophysica acta.

[16]  P. Fernyhough,et al.  The role of aberrant mitochondrial bioenergetics in diabetic neuropathy , 2013, Neurobiology of Disease.

[17]  Kevin H. Lin,et al.  PPARγ regulates the mitochondrial dysfunction in human neural stem cells with tumor necrosis factor alpha , 2013, Neuroscience.

[18]  L. Harhaji-Trajković,et al.  Autophagy-dependent and -independent involvement of AMP-activated protein kinase in 6-hydroxydopamine toxicity to SH-SY5Y neuroblastoma cells. , 2012, Biochimica et biophysica acta.

[19]  S. Yamagishi,et al.  Pravastatin inhibits advanced glycation end products (AGEs)-induced proximal tubular cell apoptosis and injury by reducing receptor for AGEs (RAGE) level. , 2012, Metabolism: clinical and experimental.

[20]  M. Chiang,et al.  Beta-adrenoceptor pathway enhances mitochondrial function in human neural stem cells via rotary cell culture system , 2012, Journal of Neuroscience Methods.

[21]  R. de Cabo,et al.  SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. , 2012, Cell metabolism.

[22]  A. Salminen,et al.  AMP-activated protein kinase (AMPK) controls the aging process via an integrated signaling network , 2012, Ageing Research Reviews.

[23]  M. Chiang,et al.  PPARgamma rescue of the mitochondrial dysfunction in Huntington's disease , 2012, Neurobiology of Disease.

[24]  M. Kim,et al.  Neuroprotection with metformin and thymoquinone against ethanol-induced apoptotic neurodegeneration in prenatal rat cortical neurons , 2012, BMC Neuroscience.

[25]  M. Chiang,et al.  The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease. , 2011, Biochimica et biophysica acta.

[26]  H. Soininen,et al.  AMP‐activated protein kinase: a potential player in Alzheimer’s disease , 2011, Journal of neurochemistry.

[27]  R. Roth,et al.  GPA protects the nigrostriatal dopamine system by enhancing mitochondrial function , 2011, Neurobiology of Disease.

[28]  S. Chowdhury,et al.  Effect of metformin on oxidative stress, nitrosative stress and inflammatory biomarkers in type 2 diabetes patients. , 2011, Diabetes research and clinical practice.

[29]  R. Scarpulla,et al.  Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. , 2011, Biochimica et biophysica acta.

[30]  V. Srikanth,et al.  Advanced glycation endproducts and their receptor RAGE in Alzheimer's disease , 2011, Neurobiology of Aging.

[31]  A. Salminen,et al.  AMP-activated protein kinase inhibits NF-κB signaling and inflammation: impact on healthspan and lifespan , 2011, Journal of Molecular Medicine.

[32]  N. Sonenberg,et al.  Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain , 2011, Molecular pain.

[33]  D. Hardie,et al.  Development of protein kinase activators: AMPK as a target in metabolic disorders and cancer. , 2010, Biochimica et biophysica acta.

[34]  I. Cho,et al.  Resveratrol Protects Mitochondria against Oxidative Stress through AMP-Activated Protein Kinase-Mediated Glycogen Synthase Kinase-3β Inhibition Downstream of Poly(ADP-ribose)polymerase-LKB1 Pathway , 2009, Molecular Pharmacology.

[35]  Zi-lin Sun,et al.  PPARγ-mediated advanced glycation end products regulation of neural stem cells , 2009, Molecular and Cellular Endocrinology.

[36]  B. Kemp,et al.  AMPK in Health and Disease. , 2009, Physiological reviews.

[37]  V. Choubey,et al.  PGC-1α and PGC-1β Regulate Mitochondrial Density in Neurons* , 2009, The Journal of Biological Chemistry.

[38]  Gaochao Zhou,et al.  AMPK: an emerging drug target for diabetes and the metabolic syndrome. , 2009, Cell metabolism.

[39]  G. Ronnett,et al.  AMPK in the brain: its roles in energy balance and neuroprotection , 2009, Journal of neurochemistry.

[40]  Charles D. Smith,et al.  Human cerebral neuropathology of Type 2 diabetes mellitus. , 2009, Biochimica et biophysica acta.

[41]  R. Ramasamy,et al.  Tempering the wrath of RAGE: An emerging therapeutic strategy against diabetic complications, neurodegeneration, and inflammation , 2009, Annals of medicine.

[42]  N. Raghavachari,et al.  PGC-1α Integrates Insulin Signaling, Mitochondrial Regulation, and Bioenergetic Function in Skeletal Muscle* , 2008, Journal of Biological Chemistry.

[43]  S. Yamagishi,et al.  Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications , 2008, Expert opinion on investigational drugs.

[44]  T. Cooper,et al.  Ethanol alters lipid profiles and phosphorylation status of AMP‐activated protein kinase in the neonatal mouse brain , 2007, Journal of neurochemistry.

[45]  B. Spiegelman,et al.  AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1α , 2007, Proceedings of the National Academy of Sciences.

[46]  J. Burnell,et al.  Methylglyoxal impairs glucose metabolism and leads to energy depletion in neuronal cells—protection by carbonyl scavengers , 2007, Neurobiology of Aging.

[47]  D. Befroy,et al.  Aging-Associated Reductions in AMP-Activated Protein Kinase Activity and Mitochondrial Biogenesis , 2007, Cell metabolism.

[48]  J. Shyy,et al.  Statins Activate AMP-Activated Protein Kinase In Vitro and In Vivo , 2006, Circulation.

[49]  M. Suwa,et al.  Metformin increases the PGC-1alpha protein and oxidative enzyme activities possibly via AMPK phosphorylation in skeletal muscle in vivo. , 2006, Journal of applied physiology.

[50]  S. Vannucci,et al.  Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. , 2005, Glycobiology.

[51]  T. Imaizumi,et al.  Diabetic vascular complications: pathophysiology, biochemical basis and potential therapeutic strategy. , 2005, Current pharmaceutical design.

[52]  D. Bennett,et al.  Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. , 2004, Archives of neurology.

[53]  B. Kuhla,et al.  Differential effects of “Advanced glycation endproducts” and β-amyloid peptide on glucose utilization and ATP levels in the neuronal cell line SH-SY5Y , 2004, Journal of Neural Transmission.

[54]  D. Hardie.  Printed in U.S.A. Copyright © 2003 by The Endocrine Society doi: 10.1210/en.2003-0982 Minireview: The AMP-Activated Protein Kinase Cascade: The Key Sensor of Cellular Energy Status , 2022 .

[55]  Paul J Thornalley.  Use of aminoguanidine (Pimagedine) to prevent the formation of advanced glycation endproducts. , 2003, Archives of biochemistry and biophysics.

[56]  P. J. Koudstaal,et al.  Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI , 2003, Diabetologia.

[57]  P. Puigserver,et al.  Peroxisome proliferator-activated receptor-gamma coactivator 1 alpha (PGC-1 alpha): transcriptional coactivator and metabolic regulator. , 2003, Endocrine reviews.

[58]  B. Kuhla,et al.  Differential effects of "advanced glycation endproducts" and ??-amyloid peptide on glucose utilization and ATP levels in the neuronal cell line SH-SY5Y , 2002 .

[59]  L. Launer,et al.  Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: The Honolulu-Asia Aging Study. , 2002, Diabetes.

[60]  S. J. Kim,et al.  The regulation of AMP-activated protein kinase by H(2)O(2). , 2001, Biochemical and biophysical research communications.

[61]  C MacKnight,et al.  Estimating the Prevalence of Dementia in Elderly People: A Comparison of the Canadian Study of Health and Aging and National Population Health Survey Approaches , 2001, International Psychogeriatrics.

[62]  R. Natarajan,et al.  Evidence that pioglitazone, metformin and pentoxifylline are inhibitors of glycation. , 2000, Clinica chimica acta; international journal of clinical chemistry.

[63]  S. Duis,et al.  Learning and hippocampal synaptic plasticity in streptozotocin-diabetic rats: interaction of diabetes and ageing , 2000, Diabetologia.

[64]  M. Lagarde,et al.  Reaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formation. , 1999, Biochemical pharmacology.

[65]  A Hofman,et al.  Diabetes mellitus and the risk of dementia , 1999, Neurology.

[66]  V. Mootha,et al.  Mechanisms Controlling Mitochondrial Biogenesis and Respiration through the Thermogenic Coactivator PGC-1 , 1999, Cell.

[67]  R. Stewart,et al.  Type 2 diabetes mellitus, cognitive impairment and dementia , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[68]  D. Hardie,et al.  AMP-activated protein kinase is activated by low glucose in cell lines derived from pancreatic beta cells, and may regulate insulin release. , 1998, The Biochemical journal.

[69]  B. Mignotte,et al.  Mitochondria and apoptosis. , 1998, European journal of biochemistry.

[70]  A. Ott.  Risk of dementia: The Rotterdam Study , 1997 .

[71]  P. Magistretti,et al.  Cellular Mechanisms of Brain Energy Metabolism. Relevance to Functional Brain Imaging and to Neurodegenerative Disorders a , 1996, Annals of the New York Academy of Sciences.

[72]  A. McCall.  The Impact of Diabetes on the CNS , 1992, Diabetes.

[73]  M. Chiang,et al.  Rosiglitazone promotes neurite outgrowth and mitochondrial function in N2A cells via PPARgamma pathway. , 2014, Mitochondrion.

[74]  M. Zou,et al.  AMPK: a cellular metabolic and redox sensor. A minireview. , 2014, Frontiers in bioscience.

[75]  B. Spiegelman,et al.  AMP-activated protein kinase (AMPK) action in skeletal muscle via direct phosphorylation of PGC-1alpha. , 2007, Proceedings of the National Academy of Sciences of the United States of America.

[76]  X. Leverve,et al.  Neuroprotective Role of Antidiabetic Drug Metformin Against Apoptotic Cell Death in Primary Cortical Neurons , 2007, Journal of Molecular Neuroscience.

[77]  David Carling,et al.  The AMP-activated protein kinase cascade--a unifying system for energy control. , 2004, Trends in biochemical sciences.

[78]  T. Imaizumi,et al.  Role of advanced glycation end products (AGEs) and their receptor (RAGE) in the pathogenesis of diabetic microangiopathy. , 2003, International journal of clinical pharmacology research.

[79]  G. Münch,et al.  Advanced glycation endproducts cause lipid peroxidation in the human neuronal cell line SH-SY5Y. , 2003, Journal of Alzheimer's disease : JAD.

[80]  Alan W. Stitt.  Advanced Glycation Endproducts , 1999 .